Anticoagulant treatment in stroke prevention

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Atrial fibrillation (AF) is a major risk factor for stroke.
• Cerebral ischemia and myocardial infarction necessitate preventative strategies.
• Oral anticoagulation is a cornerstone therapy in managing these conditions.

Purpose of the Study:

• To review the efficacy of long-term oral anticoagulant therapy for stroke prevention.
• To define optimal therapeutic ranges for anticoagulation intensity.
• To assess the risks associated with different anticoagulation intensities.

Main Methods:

• Literature review of studies on oral anticoagulation in stroke prevention.
• Analysis of treatment guidelines and clinical trial data.
• Evaluation of International Normalized Ratio (INR) targets and outcomes.

Main Results:

• Oral anticoagulation is the primary treatment for AF patients with vascular risk factors or recent cerebral ischemia.
• The therapy significantly reduces stroke risk post-myocardial infarction.
• An INR of 2.0-3.0 is identified as the optimal target range for stroke prevention.

Conclusions:

• Long-term oral anticoagulation is valuable for stroke prevention in specific patient groups.
• Therapeutic intensity is crucial; higher INR levels (3.0-4.5) may be hazardous in certain arterial stroke cases.
• Further research is needed to establish optimal lower-intensity anticoagulation for transient ischemic attack (TIA) or minor arterial stroke.